The IgA Nephropathy (IgAN) market across the seven major markets (7MM) is estimated at approximately USD 878 million in 2025, rising from nearly USD 730 million in 2024. The market is projected to expand at a strong CAGR of 30.5% between 2025 and 2034, reaching nearly USD 9.7 billion by 2034, with the United States representing the largest share.
In 2024, around 415,000 diagnosed prevalent cases of IgAN were reported across the 7MM. Market growth will be driven by increasing disease awareness, improved diagnostic techniques, greater use of kidney biopsies, and the introduction of innovative therapies such as povetacicept, atacicept, zigakibart, and ULTOMIRIS.
Currently approved treatments remain limited, including VANRAFIA (atrasentan) and FABHALTA (iptacopan) from Novartis, FILSPARI (sparsentan) from Travere Therapeutics, and TARPEYO/KINPEYGO (budesonide) from Asahi Kasei/Calliditas Therapeutics. However, safety concerns continue to challenge long-term treatment adoption, as corticosteroids may lead to hypertension and infections, while complement inhibitors increase infection risk. These limitations highlight the growing need for safer, targeted therapies suitable for chronic disease management, especially in pediatric and elderly populations.
Notably, in April 2025, Novartis received FDA accelerated approval for Vanrafia® (atrasentan) to reduce proteinuria in adults with primary IgAN at risk of rapid progression. In the same month, Vera Therapeutics completed enrollment in the pivotal Phase III ORIGIN trial evaluating atacicept in IgAN patients.
Overall, the IgA Nephropathy market is poised for significant expansion through 2034, supported by robust pipeline advancements and rising diagnosed patient populations.
DelveInsight’s report, “IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2034,” offers a comprehensive analysis of IgA Nephropathy, covering historical and projected epidemiological data along with detailed market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The study provides an overview of existing treatment approaches, upcoming therapies, individual drug market shares, and the present as well as anticipated IgA Nephropathy market size from 2020 to 2034 across the seven major markets. Additionally, the report evaluates treatment algorithms, growth drivers, barriers, and unmet clinical needs to identify strategic opportunities and assess the market’s long-term potential.
Request for a Free Sample Report @ IgA Nephropathy Market Forecast
Key Highlights from the IgA Nephropathy Market Report
- The combined IgA Nephropathy market size across the 7MM and China was nearly USD 500 million in 2022 and is expected to expand steadily during 2023–2034.
- In 2022, the United States accounted for the largest market share among the 7MM, generating approximately USD 160 million, with projections indicating further growth through 2034.
- Prominent companies engaged in IgA Nephropathy drug development include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis, RemeGen, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others.
- The disease shows higher incidence in males compared to females.
- Prevalence rates vary geographically, ranging from 10–20% of primary glomerulonephritis cases in the United States, 20–30% in parts of Europe, and up to 40–50% in developed Asian countries.
- A global systematic review of biopsy-based studies estimates a minimum incidence of 2.5 cases per 100,000 individuals annually. Most data originated from Europe and North America, with limited representation from Japan.
- While IgA Nephropathy may follow a relatively mild course in many individuals, a significant proportion of patients experience gradual progression to end-stage renal disease (ESRD). Approximately 15% may develop ESRD within 10 years and about 20% within 20 years, depending on disease classification criteria.
Recent Developments in the IgA Nephropathy Market
- In Febriuary 2026, Novartis announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia® (atrasentan). Vanrafia showed a difference of 2.39 ml/min/1.73m2 in estimated glomerular filtration rate (eGFR) change from baseline vs. placebo (2-sided p = 0.057) at Week 136, 4 weeks after the end of study treatment.
- In January 2026, Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced the atacicept Biologics License Application (BLA) for the treatment of adults with immunoglobulin A nephropathy (IgAN) was accepted for Priority Review by the U.S. Food and Drug Administration (FDA). The BLA, which was submitted using the Accelerated Approval Program, was assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 7, 2026. If approved, atacicept could offer patients an autoinjector for at-home self-administration of a once-weekly subcutaneous injection.
- In November 2025, Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the U.S. Food and Drug Administration (FDA) has granted accelerated approval of VOYXACT (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. VOYXACT is a self-administered, subcutaneous injection dosed every four weeks. VOYXACT was granted accelerated approval based on the VISIONARY Phase 3 interim analysis, where it achieved a significant placebo-adjusted treatment effect of 51% (P<0.0001) reduction in proteinuria at nine months (n=320) of treatment (-50% VOYXACT vs 2% placebo). VOYXACT is the first and only therapy to block A-PRoliferation-Inducing-Ligand (APRIL).
- In August 2025, Travere Therapeutics announced FDA approval of updated REMS labeling for FILSPARI® (sparsentan), used to treat IgA nephropathy (IgAN). The update reduces liver function monitoring to every three months and removes the embryo-fetal toxicity monitoring requirement.
- In May 2025, Otsuka and OPDC announced that the FDA has accepted the Biologics License Application for sibeprenlimab, an investigational antibody targeting APRIL, for the treatment of adults with IgA nephropathy (IgAN).
- In April 2025, Novartis announced that the FDA has granted accelerated approval for Vanrafia® (atrasentan), an oral endothelin A receptor antagonist, to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid progression (UPCR ≥1.5 g/g). Vanrafia is taken once daily alongside standard supportive care.
- On May 25, 2024, Novartis announced positive Phase III results for atrasentan, demonstrating clinically meaningful proteinuria reduction and strengthening its IgA Nephropathy portfolio. Atrasentan is an investigational, selective oral endothelin A (ETA) receptor antagonist currently under Phase III evaluation for IgAN. The ALIGN study (NCT04573478) is a global, randomized, double-blind, placebo-controlled trial assessing the drug’s safety and efficacy in patients at risk of progressive kidney function decline.
- On May 24, 2024, HI-Bio presented encouraging interim findings from the Phase II IGNAZ study evaluating felzartamab in IgA Nephropathy at the 61st European Renal Association Congress. Felzartamab is a human monoclonal antibody targeting CD38 on mature plasma cells and has demonstrated the ability to selectively reduce CD38-positive plasma cells, potentially improving outcomes in antibody-mediated conditions.
- On May 28, 2024, Vera Therapeutics announced that the U.S. FDA granted Breakthrough Therapy Designation to atacicept for IgA Nephropathy treatment. This decision was based on Phase IIb ORIGIN trial results. Atacicept is a recombinant fusion protein designed to target B cells and plasma cells to lower autoantibody production, positioning it as a potential best-in-class therapy.
IgA Nephropathy Overview
IgA Nephropathy, also referred to as Berger’s disease, is a chronic kidney condition characterized by the accumulation of immunoglobulin A (IgA) antibodies in the renal glomeruli. This immune-mediated deposition leads to inflammation and progressive damage to the kidney’s filtration units.
Although the precise etiology remains unclear, the disorder is believed to result from a combination of genetic susceptibility and environmental triggers, including infections and autoimmune responses. Early manifestations may include hematuria (blood in urine) and proteinuria, though some individuals remain symptom-free for extended periods.
Over time, the disease may advance to chronic kidney disease and potentially kidney failure. Management strategies focus on symptom control, blood pressure regulation, reduction of inflammation, and slowing disease progression through pharmacological interventions, dietary measures, and lifestyle modifications. Continuous monitoring and regular medical follow-ups are essential for optimal disease management.
Learn more about IgA Nephropathy treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ IgA Nephropathy Prevalence
IgA Nephropathy Market Outlook
The report provides a detailed evaluation of historical, current, and future market trends, examining how existing and emerging therapies address unmet needs and influence market expansion. It analyzes critical parameters such as therapy cost, mechanism of action, patient eligibility criteria, compliance rates, anticipated launch timelines, competitive positioning, and expert opinions.
Comprehensive tables and graphical representations present clear market projections, enabling stakeholders to assess growth potential efficiently. According to DelveInsight, the IgA Nephropathy market across the 7MM is expected to undergo significant transformation between 2020 and 2034.
IgA Nephropathy Epidemiology
DelveInsight estimates that approximately 415,000 diagnosed prevalent cases of IgA Nephropathy (IgAN) were reported across the seven major markets (7MM) in 2024, with cases expected to increase at a modest CAGR of 0.6% through 2034.
The United States accounted for about 133,000 cases in 2024, while Japan recorded the highest burden among the 7MM with nearly 175,000 cases, both projected to rise by 2034. Within the EU4 and the UK, Germany had the highest number of cases (around 30,000), whereas Spain reported the lowest (approximately 5,000).
Gender-specific data from France showed roughly 16,000 male and 8,000 female diagnosed cases in 2024, with continued growth anticipated. In the UK, age-wise distribution included approximately 2,000 cases (, 11,000 (18–45 years), 11,000 (46–65 years), and 3,000 (>65 years) in 2024, all expected to increase by 2034.
Explore more about IgA Nephropathy Epidemiology @ IgA Nephropathy Market Dynamics
IgA Nephropathy Drug Uptake
Povetacicept (ALPN-303) – Vertex Pharmaceuticals
Povetacicept is a dual BAFF and APRIL inhibitor designed to regulate abnormal B-cell activity, a key driver in IgA Nephropathy (IgAN). Built using a TACI-based platform, it has demonstrated stronger binding affinity and improved potency in preclinical studies compared to earlier BAFF/APRIL inhibitors. Clinical findings suggest best-in-class potential with disease-modifying capability.
Vertex Pharmaceuticals is currently conducting the global Phase III RAINIER trial across the US, Europe, and Asia. Interim cohort enrollment is expected to be completed in 2025, with plans to seek accelerated approval in the US based on 36-week data. The program became a core immunology asset for Vertex following its USD 5 billion acquisition of Alpine Immune Sciences in May 2024.
Atacicept – Vera Therapeutics
Atacicept is a recombinant fusion protein that blocks BAFF and APRIL, targeting the immune pathways responsible for B-cell survival and autoantibody production in IgAN. In May 2024, the US FDA granted Breakthrough Therapy Designation, reflecting its potential to deliver meaningful clinical benefit.
Vera Therapeutics has completed full enrollment in the Phase III ORIGIN trial (April 2025). A 200-patient primary endpoint cohort will provide 36-week UPCR data to support a planned Biologics License Application (BLA) submission following topline results expected in Q2 2025. Additionally, the PIONEER study, scheduled for 2025, will evaluate atacicept in broader and higher-risk IgAN populations, including patients with advanced kidney impairment and post-transplant recurrence.
Zigakibart (FUB523) – Novartis
Zigakibart is a subcutaneous monoclonal antibody targeting APRIL and is currently in Phase III development for IgAN, with regulatory submission anticipated in 2027. Earlier Phase I/II studies confirmed safety and supported dose selection (600 mg biweekly) for late-stage trials.
The therapy received Orphan Drug Designation from the European Commission in July 2022. Strengthening its renal pipeline, Novartis acquired Chinook Therapeutics in August 2023 for up to USD 3.5 billion, integrating zigakibart into its advanced nephrology portfolio.
Request for a sample report to understand more about the IgA Nephropathy pipeline development activities @ IgA Nephropathy Therapies and Drugs
IgA Nephropathy Therapeutic Landscape
Leading pharmaceutical companies actively developing innovative IgA Nephropathy treatments include Calliditas Therapeutics AB (NASDAQ: CALT), Travere Therapeutics, Inc. (NASDAQ: TVTX), Omeros Corporation (NASDAQ: OMER), Novartis Pharmaceuticals (SWX: NOVN), Chinook Therapeutics, Inc. (NASDAQ: KDNY), Vera Therapeutics, Inc. (NASDAQ: VERA), and Otsuka Pharmaceutical (TYO: 4578), among others.
Learn more about the emerging IgA Nephropathy therapies & key companies @ IgA Nephropathy Clinical Trials and FDA Approvals
Key Report Insights
- Patient population analysis
- Market size and growth trends
- Competitive landscape assessment
- Market drivers and barriers
- Growth opportunities
- Treatment strategies
- Pipeline evaluation
- Current treatment algorithms
- Impact of emerging therapies
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
